HOME >> BIOLOGY >> NEWS
After 2 years, study shows Revlimid patients live longer and remain transfusion free

Orlando, FL (December 11, 2006) -- Dr. Alan List, from the H. Lee Moffitt Cancer Center & Research Institute, presented the final results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) at this years American Society of Hematology (ASH) meeting. This breakthrough data showed that in MDS patients with chromosome 5q deletion treatment with Revlimid can provide long-term durable results and help them to achieve blood transfusion independence and remain transfusion free.

"These landmark data demonstrate that Revlimid, in many cases, eliminates all signs of the cancers genetic cause, on partial deletion of chromosome 5, and as a consequence reduce or even eliminate the need for transfusions in many patients with MDS. After over two years of follow up, these responses have sustained," said List, Professor of Oncology and Medicine and Chief, Division of Hematology Malignancies at Moffitt, and lead investigator of the study. "It is very rewarding to see patients treated with Revlimid, living longer, living three or four years transfusion free and having a better quality of life overall."

MDS, a cancer in which the bone marrow fails to make enough functioning blood cells, affects 300,000 people worldwide killing 60,000 to 70,000 a year. MDS patients suffer from anemia and fatigue and need whole-body blood transfusions as much as twice a month. Repeated transfusions can lead to a toxic buildup called "iron overload" that severely damages the heart, liver and pancreas, and patients eventually succumb to the disease.

The data presented by List showed that two-thirds of patients who received Revlimid were completely freed from the need for blood transfusions. More significantly, in 44 percent of patients, there was no detectable trace of the cancer and after two years of follow-up the median duration has not yet been achieved.

Additional data o
'"/>


11-Dec-2006


Page: 1 2

Related biology news :

1. After a decades-long search, scientists identify new genetic risk factors for multiple sclerosis
2. After scrutiny, preemie lung treatments turn out to be safe, effective
3. After North Korea test, what can be done to reduce the growing nuclear threat?
4. After insects attack, plants bunker sugars for later regrowth
5. After the Hurricanes
6. After the yeast is gone bacteria continue to develop flavor of sparkling wine
7. After a time-shift, mixed signals from the circadian clock
8. After flu exposure, mild exercise protects mature mice from dying
9. Allergy battle could be won in five years, says scientist
10. New study warns limited carbon market puts 20 percent of tropical forest at risk
11. Clones on task serve greater good, evolutionary study shows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/27/2019)... ... October 26, 2019 , ... Since 2010, The HOTH has served over 200,000 ... success of their clients, they’ve earned a place on the highly-competitive and desirable Inc. ... many additional awards and accolades along the way. , Now, The HOTH ...
(Date:10/26/2019)... (PRWEB) , ... October 24, 2019 , ... World Cord ... for parents, doctors, nurses, and midwives to learn about the current and future uses ... , Cord blood is now being used to treat and cure over 80 different ...
(Date:10/26/2019)... PLATA, Md. (PRWEB) , ... October 25, 2019 ... ... an in-office training on myofunctional therapy in La Plata, MD. Orofacial myofunctional disorders ... how a patient eats, sleeps and speaks. This can include anything from difficulty ...
Breaking Biology News(10 mins):
(Date:11/2/2019)... YORK (PRWEB) , ... October 31, 2019 , ... ... been released by pharma artificial intelligence pioneer tellic. drug360 brings tellic’s expertise ... This new tool allows researchers to quickly uncover relationships between genes, diseases, variants, ...
(Date:10/29/2019)... ... 29, 2019 , ... Modality Solutions, a biopharmaceutical ... chain validation workshop at the Biomanufacturing World Summit (BMWS19) Conference, November 11-12, 2019, ... Biomanufacturing World Summit brings together pharmaceutical executives, cutting-edge technology providers, and ...
(Date:10/22/2019)... SOMERSET, N.J. (PRWEB) , ... October 22, 2019 , ... ... Director, Clinical Supply Services and Drug Product Technologies Integration, will participate in a panel ... Logistics Conference (HPCLC), to be held at the Gwen Hotel, Chicago, on Oct. 28-30, ...
(Date:10/17/2019)... HAVEN, Conn. (PRWEB) , ... October 16, 2019 ... ... company that provides personalized, easy-to-understand, web-based genetic counseling information, has published a new ... a five year period and provides guidance as to how patients and medical ...
Breaking Biology Technology:
Cached News: